A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
| 适应症 | Uveal Melanoma |
|---|---|
| 分期 | 2期 |
| 申办方 | Dana-Farber Cancer Institute |
| 状态 | 提前终止 |
| 受试者人数 | 13 人 |
| 干预（药物） | BVD-523 |
| 开始日期 | 2018年3月26日 |
| 完成日期 | 2020年5月5日 |
| 结果公布日 | 2021年11月11日 |
摘要
This research study is studying a targeted therapy called BVD-523 as a possible treatment for advanced uveal melanoma.
Overall Response Rate
| BVD-523 | 0 percentage of participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)